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Abstract
Background: OK-432, penicillin-killed Streptococcus pyogenes, is used in treating lymphangiomas
and carcinomas. We have studied in vitro the role of mononuclear phagocytes (MNPs), including
purified monocytes (MOs), in the immune response to OK-432. MIP-1α/β and MCP-1 secretions
were assessed in whole blood (WB), peripheral blood mononuclear cells (PBMCs) and purified
MOs, after in vitro stimulation with OK-432 with or without adherence for 24 hours.
Results: OK-432 stimulated MNPs to secrete MCP-1 and MIP-1α/β in healthy individuals and in
head and neck squamous cell carcinoma (HNSCC) patients, except for OK-432 stimulation of WB
giving a minimal MIP-1α/β response. Upon culture on low-attachment wells, a spontaneous
chemokine secretion was observed, with an unchanged secretion following OK-432 stimulation.
Inhibition of Syk kinase and/or PI-3 kinase did not significantly change the chemokine response to
OK-432, except for MIP-1α production being increased upon Syk inhibitor addition and an
increased MCP-1 response upon addition of both inhibitors. Adhesion may possibly involve β1 and/
or β3 integrins, not β2, whereas β1–3 integrins may act as co-stimulatory receptors for OK-432.
Based on direct blockage of CD36 or CD18 by antibodies, MCP-1 production may be mediated by
CD18 while MIP-1β and MCP-1 production may occur upon binding to CD36.
Conclusion: Adherent human MOs produce MCP-1 and MIP-1α/β upon stimulation with OK-432.
CD36 modulates MIP-1β and MCP-1 response. Thus, to some extent OK-432 acts as a substance
whereby only MOs adhered to surfaces secrete MCP-1 and MIP-1α/β, in part explaining why OK-
432 is suited as a biological response modifying drug.
Background
The innate immune system detects and eliminates invad-
ing foreign material through non-specific defense mecha-
nisms elicited by, e.g., mononuclear phagocytes (MNP).
MNPs originate as monoblasts in the bone marrow, reside
as monocytes (MOs) in blood and become, e.g., tissue
macrophages (Mϕs) or dendritic cells (DCs) upon
extravasation into tissues. The innate immune system is
presumably involved when biological response modifiers
(BRMs) are utilized in the treatment of diseases such as
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cancer [1,2] and lymphangiomas [3]. Killed bacterial tox-
ins [4] along with bacillus Calmette-Guerin (BCG) [5], β-
glucan [6], interferons [7] and monoclonal antibodies [8]
are examples of BRMs used in cancer treatment.
Japan has a long standing tradition in using penicillin-
killed lyophilized Streptococcus pyogenes, denominated
OK-432 or picibanil, as a biological response modifier
(BRM) for treatment of cancer [1,2]. Sakamoto et al. [1]
published in 2001 a meta-analysis showing a 20% 5-year
survival improvement with immunochemotherapy, com-
pared to chemotherapy alone, following OK-432 treat-
ment in patients diagnosed with non-small-cell lung
cancer. This meta-analysis was based on 1,520 patients
enrolled in 11 randomized clinical phase III trials. Fur-
thermore, Oba et al [2] published in 2007 a meta-analysis
including 8009 gastric carcinoma patients from 8 rand-
omized clinical phase III trials and concluded that com-
pared to control conditions, addition of OK-432
treatment increased survival. There are also reports sug-
gesting that patients with other cancers, such as head and
neck squamous cell carcinoma (HNSCC) [9], may benefit
from OK-432 treatment. OK-432 has also been used as a
maturation factor for DCs cells as part of vaccination ther-
apy of cancer patients [10].
Lymphangiomas are benign neoplasias of lymphatic ori-
gin, often congenital, that may extend around vital struc-
tures [11]. Surgical removal of lymphangiomas has been
the standard treatment, but may be technically difficult.
Injection of OK-432 into cystic lymphangioma lesions
may lead to shrinkage and subsequent cure as first
reported by Ogita [3]. Today, injection with OK-432 is
established as a major treatment option for lymphangi-
omas [11], and is an important example of the use of
BRMs in medicine.
OK-432 presumably exerts its effect by activating the
immune system to secrete toxic substances, which in turn
eliminate tumor cells [12]. It is, however, relatively little
known about the mechanisms of action of OK-432. The
principal cells responding to the drug, the engaged recep-
tors or signal transduction pathways, are to a surprisingly
large extent unknown. This should be an important area
of study. The efficiency of OK-432 treatment needs to be
improved in order to make OK-432 a better cancer treat-
ment drug. Additional drugs, which could improve OK-
432's response, as well as studying to what extent other
(cancer) drugs potentially interfere with the receptors and
signal transduction pathways driving the OK-432
response, should therefore be determined as to optimize
and improve treatment.
Furthermore,S. pyogenes is an important pathogen causing
human disease. The diseases caused by S. pyogenes range
from tonsillitis, impetigo, necrotizing fasciitis, and scarlet
fever to lethal toxic shock syndrome [13]. Thus, studying
the interactions of OK-432 with the immune system may
shed light into the biology of these diseases as well.
One major MNP function is secretion of chemokines,
such as monocyte chemoattractant protein (MCP) -1 and
macrophage inflammatory protein (MIP) -1α/β [14].
Chemokines have been shown to be secreted in response
to OK-432 stimulation [15] and have the main effect of
attracting new leucocytes to the site from where they are
secreted [16]. It should be of interest, to determine the
modality of chemokine secretion from MOs and Mϕs
upon OK-432 stimulation. We have therefore found it
pertinent to address this issue in the present investigation.
Priming provided by adherence, presumably associated
with MNP differentiation from MO to Mϕ, contributes to
interleukin secretion following OK-432 MNP stimulation
[17]. Therefore, it is of interest to study to what extent the
MNP chemokine response to OK-432 depends on adher-
ence. Molecularly, we have found it relevant to investigate
the role of β-integrin receptors, as these receptors partici-
pate during differentiation of MNP from MO to Mϕ. Fur-
thermore, these receptors may be functionally blocked by
addition of piceatannol (Syk kinase inhibitor) and/or
LY294002 (phosphoinositide (PI)-3 kinase inhibitor)
[18-22]. OK-432 may stimulate TLR receptors. In addition
to OK-432, we have studied chemokine secretion upon
stimulation with the known TLR2 agonist LTA and TLR4
agonist LPS. Moreover, we explored the role of the TLR2
co-receptor CD36 [23] in OK-432 stimulation.
We have determined that in vitro purified adherent MNPs
may secrete chemokines MCP-1, MIP-1α and MIP-1β fol-
lowing OK-432 stimulation. MOs deprived of adherence
did not respond to OK-432 stimulation as assessed by
chemokine secretion. Inhibition of Syk and PI-3 kinase
did not block the stimulatory effect of OK-432. MIP-1α/β
production in WB and MOs was higher upon stimulation
with LTA or LPS while OK-432 stimulation gave a higher
MCP-1 secretion in WB and MOs in comparison with LTA
or LPS. CD36, and to some extent CD18, participate in the
OK-432-modulated MNP chemokine response.
Results
In vitro chemokine production in unstimulated cultures
Upon adherence, only MCP-1 was to some extent secreted
(Fig. 1). Upon low adherence conditions, MCP-1 and
MIP-1α/β were secreted at all studied conditions (Fig. 1).
Chemokine production following OK-432 stimulation
At all tested regular growth conditions, OK-432 stimu-
lated the release of MIP-1α/β, and MCP-1 (all p < 0.05)
(Fig. 2). We determined a similar secretion for MCP-1 andBMC Immunology 2009, 10:6 http://www.biomedcentral.com/1471-2172/10/6
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MIP-1α/β upon stimulating PBMCs versus MOs (Fig. 2).
Stimulated WB gave a lower MIP-1α secretion compared
to PBMCs or MOs (Fig. 2). The effect of OK-432 was also
tested with MOs from HNSCC patients giving the same
chemokine response profile as healthy controls (Fig. 2).
With respect to MCP-1, close correlation between protein
levels and mRNA levels was observed in three healthy
donors (Fig. 3A) as well as two HNSCC patients, tested on
two separate days (Fig. 3C) suggesting a pre-transcrip-
tional regulation upon in vitro OK-432 stimulation of
MOs.
Chemokine production following OK-432 versus LTA or 
LPS stimulation
Tested were WB (Fig. 4) and MOs (Fig. 5) stimulated in
parallel with OK-432 or LTA (TLR2 ligand) or LPS (TLR4
ligand). In WB stimulated with OK-432 or LTA, the
response was primarily seen with MCP-1, and only to
some extent with MIP-1α/β, whereas the LPS-stimulated
response was determined by MIP-1α/β secretion. In puri-
fied MOs, OK-432 and LTA stimulated secretion of MCP-
1. LPS inhibited MCP-1 production. Thus, it appears that
OK-432 stimulation is more akin to LTA than to LPS stim-
ulation.
In vitro chemokine production in unstimulated WB, PBMCs  or MOs Figure 1
In vitro chemokine production in unstimulated WB, 
PBMCs or MOs. Human WB, PBMCs or MOs were plated 
in parallel on regular (R) or low attachment (L) plates and left 
unstimulated for 24 h (A). Supernatants were then collected 
and analyzed using Multiplex (MIP) or ELISA (MCP-1). WB (n 
= 8); PBMC (MIP-1α/β: n = 7; MCP-1: n = 4); MO (n = 6).
OK-432 stimulates release of chemokines in WB, PBMCs,  and isolated human MOs from healthy donors and HNSCC  patients Figure 2
OK-432 stimulates release of chemokines in WB, 
PBMCs, and isolated human MOs from healthy 
donors and HNSCC patients. Human WB, PBMCs or 
MOs were stimulated with media or OK-432 (0.01 KE/ml) 
for 24 h (A). MOs isolated from four HNSCC patients were 
stimulated for 24 h with media or OK-432 (0.01 KE/ml) (B). 
Supernatants were then collected and analyzed using Multi-
plex (MIP) or ELISA (MCP-1). A: WB (n = 8); PBMC (n = 12); 
MO (n = 27); B: HNSCC (n = 4).
OK-432 augments MCP-1 gene expression in MOs from  healthy donors and HNSCC patients and correlates with  MCP-1 protein levels upon inhibition with piceatannol and  wortmannin Figure 3
OK-432 augments MCP-1 gene expression in MOs 
from healthy donors and HNSCC patients and corre-
lates with MCP-1 protein levels upon inhibition with 
piceatannol and wortmannin. MCP-1 gene expression 
was assessed in MOs stimulated with OK-432 for 24 h from 
three randomly selected healthy donors (A) or two HNSCC 
patients on two separate days (C). In separate experiments, 
MOs, stimulated with piceatannol (120 μM) (B) or wortman-
nin (100 nM) (D) for 30 min followed by stimulation with 
OK-432 for an additional 24 h, were analyzed by ELISA or 
real-time PCR with respect to MCP-1 production and gene 
expression, respectively. A, B, and D: n = 3; C: n = 2.BMC Immunology 2009, 10:6 http://www.biomedcentral.com/1471-2172/10/6
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Chemokine production following OK-432 stimulation of 
WB, PBMCs and MOs cultured on regular or low-
attachment culture wells
Chemokine secretion was compared in WB and MNPs cul-
tured on regular (R) or low-attachment (L) wells (Fig. 6).
In WB, the MCP-1 response was reduced by 90% at the L
compared to the R condition (48 ± 4 vs 7 ± 27 ng/ml; p <
0.02). In PBMCs, MIP-1α response was abolished at the L
condition 24 ± 9.7 vs -1 ± 5.5 ng/ml; p < 0.04). Further-
more, MIP-1β response was reduced by 74% (19 ± 3 vs 5
± 2 ng/ml; p < 0.02), and the MCP-1 response by 94% (54
± 9 vs 3.1 ± 1.7 ng/ml; p < 0.02). In MOs, MCP-1 (19.8 ±
6.4 vs -0.2 ± 0.2 ng/ml; p < 0.02) response was completely
blocked, while MIP-1α was reduced by 92% 17.9 ± 10.7
vs 1.5 ± 1.1 ng/ml; p < 0.05) and MIP-1β by 98% 12.1 ±
3.8 vs 0.2 ± 0.6 ng/ml; p < 0.03). Thus, it appears that
chemokine responses following OK-432-stimulation are
almost absent if the cells are minimally allowed to adhere
to a surface.
Chemokine production following OK-432 stimulation of 
PBMC, MO-depleted PBMCs or MOs
Chemokine secretion was determined from PBMCs, MOs
separated by adherence and MO-depleted PBMCs (Fig. 7).
MO-depleted PBMCs (PB) and MOs secreted 18% and
36% of the PBMC-derived MCP-1, respectively (Figure 7).
Thus, MOs are the major source for MCP-1 production. In
contrast, PBMCs stimulated with LPS gave a negative
MCP-1 production since stimulation with LPS gives lower
MCP-1 secretions compared to media controls.
Stimulation of MOs with OK-432 is independent of Syk 
and PI-3 kinase
In order to determine whether Syk kinase activation was
necessary for the observed chemokine production in OK-
432-stimulated MOs, the Syk kinase inhibitor piceatannol
(120 μM, (Fig. 3B), 30 μM (not shown), 1 μM (Fig. 8) or
0.5 μM (not shown), or diluent control, was added for 30
minutes to adherent MOs prior to addition of OK-432 for
24 hours. Western blot (Wb) analysis (Fig. 9) shows that
Chemokine production follows OK-432, LTA or LPS in vitro  stimulation of WB Figure 4
Chemokine production follows OK-432, LTA or LPS 
in vitro stimulation of WB. Human WB was stimulated in 
parallel with OK-432 (0.01 KE/ml), LTA (0.5 μg/ml), LPS (1 
μg/ml), or left unstimulated for 24 h. Supernatants were then 
collected and analyzed using Multiplex (MIP) or ELISA (MCP-
1). Control, OK-432, LPS: n = 8; LTA: n = 4.
OK-432, LTA or LPS in vitro stimulation of MOs Figure 5
OK-432, LTA or LPS in vitro stimulation of MOs. 
MOs were stimulated in parallel with OK-432 (0.01 KE/ml), 
LTA (0.5 μg/ml), LPS (1 μg/ml), or left unstimulated for 24 h. 
Supernatants were then collected and analyzed using Multi-
plex (MIP) or ELISA (MCP-1). MIP-1α (Control, OK-432, 
LPS: n = 9; LTA: n = 7).MIP-1β (Control, OK-432, LPS: n = 
10; LTA: n = 8); MCP-1 (Control, OK-432: n = 19; LTA: n = 
9; LPS: n = 16).
OK-432 stimulation of adherent or suspended WB, PBMCs,  and MOs Figure 6
OK-432 stimulation of adherent or suspended WB, 
PBMCs, and MOs. WB, PBMCs or MOs were stimulated 
with OK-432 (0.01 KE/ml) or left unstimulated on regular (R) 
or low-attachment (L) plates for 24 h. Supernatants were 
analyzed using Multiplex (MIP) or ELISA (MCP-1). WB: n = 8; 
PBMC: n = 8; MO: n = 6.BMC Immunology 2009, 10:6 http://www.biomedcentral.com/1471-2172/10/6
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Syk kinase becomes phosphorylated following adherence
of MOs and is further phosphorylated following OK-432
stimulation but this phosphorylation is substantially
reduced in MOs exposed to piceatannol (30 μM) for 30
min before stimulation with OK-432 for an additional 15
min. Addition of piceatannol had no effect on chemokine
production, as measured by MCP-1, in human MOs unless
it was used at high, unspecific concentrations (120 μM)
(Fig. 3B, top). With respect to mRNA, MCP-1 levels are also
reduced when exposed for 30 min to 120 μM piceatannol
followed by 24-hour incubation with OK-432 (Fig. 3B, bot-
tom). Thus, piceatannol, at high, likely unspecific, concen-
trations (120 μM) lowers MCP-1 secretion while at low,
specific, concentrations (0.5, 1 or 30 μM), has no effect on
the tested chemokines, despite exhibiting efficacy in lower-
ing Syk kinase phosphorylation.
The role of PI-3 kinase in OK-432's ability to stimulate
MOs was tested where LY294002 (Fig. 8) or Wortmannin
(Fig. 3D) was added for 30 min to freshly isolated MOs
followed by incubation with OK-432 for 24 hours. West-
ern blot analysis (Fig. 9) shows that PI-3 kinase is not
phosphorylated following adherence of MOs but
becomes phosphorylated following OK-432 stimulation.
This OK-432-dependent PI-3 kinase phosphorylation is
decreased when MOs are exposed to LY294002 for 30 min
before stimulation with OK-432 for 15 min. Addition of
LY294002 (Fig. 8B) or Wortmannin (results not shown)
did not significantly reduce MIP-1α, MIP-1β, or MCP-1
production in OK-432-stimulated MOs. Furthermore, a
combination of piceatannol (Pic) (30 μM), and
LY294002 (LY) (50 μM), or diluent control (ethanol,
EtOH), was used throughout the entire MO isolation pro-
cedure as well as during incubation with media (Fig. 8C)
or OK-432 for an additional 24 hours (Fig. 8D). Incuba-
tion with media blocked spontaneous in vitro secretion of
all tested chemokines, but no significant effect was
observed in the ability of MOs to produce MIP-1α, and
MIP-1β upon OK-432 stimulation. On the contrary, MCP-
1 production appears to be augmented following OK-432
stimulation, pointing to the existence of an additional
MCP-1 pathway, dependent on Syk and PI-3 kinase,
throughout the isolation and adherence protocol.
Role of β2-integrin (CD18) during stimulation of MOs with 
OK-432
Treating MOs with a neutralizing F(ab) – anti-CD18 anti-
body (Fig. 10A) prior to OK-432 stimulation, the secre-
tion of MCP-1 (statistically nonsignificant), but not the
other tested chemokines, decreased. Thus, the β2 integrin
(CD18) may possibly be involved in MCP-1 secretion fol-
lowing OK-432 activation of human isolated MOs.
MO-depleted PBMCs secrete less chemokines than PBMCs  upon OK-432 stimulation Figure 7
MO-depleted PBMCs secrete less chemokines than 
PBMCs upon OK-432 stimulation. PBMCs, MOs, or PBs 
(MO-depleted PBMCs) were left unstimulated or stimulated 
in parallel with OK-432 (0.01 KE/ml) or LPS (1 μg/ml) for 24 
h. Supernatants were analyzed using Multiplex (MIP) or ELISA 
(MCP-1). n = 2.
Syk and PI-3 kinase-independent signaling for OK-432 stimu- lation of MOs Figure 8
Syk and PI-3 kinase-independent signaling for OK-
432 stimulation of MOs. Piceatannol (1 μM) or diluent 
control was added to MO cultures for 30 min prior to addi-
tion of OK-432 for 24 h (A). LY294002 (50 μM) was added 
to MOs for 30 min prior to addition of OK-432 for 24 h (B). 
In separate experiments, a combination of LY294002 (50 
μM) and piceatannol (30 μM) was added to whole blood and 
throughout the monocyte isolation procedure (C) and fol-
lowed by stimulation with OK-432 or left unstimulated for 
24 h (D). Supernatants were analyzed using Multiplex (MIP) 
or ELISA (MCP-1). A: n = 4; B: n = 5; C: n = 4; D: n = 4.BMC Immunology 2009, 10:6 http://www.biomedcentral.com/1471-2172/10/6
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Role of CD36 on stimulation of MOs with OK-432
Anti-CD36 antibody or isotype control was added to wells
followed by addition of PBMCs, incubated for 40 min,
and OK-432 was added for an additional 24 hours (Fig.
10B). CD36 addition decreased MIP-1β and MCP-1 (both
p = 0.028) but not MIP-1α secretion. Thus, in MOs, OK-
432 elicits both MIP-1β and MCP-1 production in part via
CD36 acting as a co-receptor.
Discussion
We have studied in vitro OK-432-stimulated mononuclear
MNPs chemokine secretion. Purified MOs, PBMCs or WB
secreted MCP-1, MIP-1α, and MIP-1β following OK-432
stimulation at a similar rate, except for a substantially
lower MIP-1α secretion from WB. This is in line with other
investigators, e.g., showing that S. pyogenes directly acti-
vates Mϕs to secrete chemokines [24]. Cytokine mRNA
quantification of MCP-1 transcripts showed that OK-432
stimulation was followed by cytokine mRNA synthesis
within hours. There was a correlation between measured
cytokine mRNA levels and cytokine-secreted levels sug-
gesting that OK-432 mainly exerts its effects at the pre-
transcriptional level. We furthermore separated by adher-
ence most of the MOs from a sample of PBMCs. Upon
OK-432 stimulation both these cell fractions secreted
MCP-1 at about twice the level of the MO-depleted frac-
tion. These findings support that MNPs are the main
source for MCP-1 within PBMCs. OK-432 also elicited a
chemokine response in purified MOs from HNSCC
patients.
All studied chemokines were secreted without particular
stimulation factors at low adherence conditions,
whereas MIP-1α/β secretion was completely inhibited by
adherence. At low adherence conditions, the secretion
response of MIP-1α/β and MCP-1 from PBMCs and MOs
was abolished upon OK-432 stimulation. This might
indicate that MNPs undergoing adherence fundamen-
tally alter their chemokine secretion responses and sup-
ports that MO to Mϕ differentiation interferes with the
regulation of chemokine secretion. This is also sup-
ported by our observations of MIP-1α-derived OK-432
stimulated secretion being lower in WB compared to
PBMCs and MOs. Diapedesis depends on, e.g., integrin
receptor engagement co-triggering differentiation of
MOs to Mϕs [18]. Such stimulation may be provided
when MOs are isolated by in vitro adherence. Syk phos-
phorylation is a necessary part of β1–3 integrin-generated
activation [19-21], whereas PI-3 kinase phosphorylation
is required in β2 integrin-generated activation [20]. We
have presently shown that adherence of MOs stimulated
phosphorylation of Syk but not PI-3 kinase, as deter-
mined by Western blots. Thus, it appears that possibly
both β1 and αvβ3 integrins, but not β2 integrin, play a role
in mediating MO adhesion. Based on Western blots,
binding of OK-432 to MOs elicited a higher Syk phos-
phorylation compared to unstimulated MOs, possibly
suggesting an adherence-mediated priming effect. PI-3
OK-432 promotes Syk or PI-3 kinase phosphorylation in  MOs Figure 9
OK-432 promotes Syk or PI-3 kinase phosphorylation 
in MOs. MOs, isolated by the monocyte negative isolation 
kit, were incubated either with piceatannol, Pic. (30 μM) or 
diluent control (A) or LY294002, LY (50 μM) (B) and either 
left unstimulated or further stimulated with OK-432 for 15 
min. Blots shown are representative of two separate experi-
ments performed with pooled MOs obtained from two dif-
ferent blood donors.
Role of CD18 and CD36 in OK-432 activation of MOs Figure 10
Role of CD18 and CD36 in OK-432 activation of MOs. 
MOs were incubated either with isotype control or anti-
CD18/F(ab) (12.5 μg/ml) for 24 h (A). PBMCs were incu-
bated either with isotype control or anti-CD36 (2.5 μg/ml) 
(B) prior to incubation with OK-432 for 24 h. Supernatants 
were analyzed for shown chemokines by Multiplex (MIP) or 
ELISA (MCP-1). A: n = 3; B: n = 6. CD18: MCP-1 (NS).BMC Immunology 2009, 10:6 http://www.biomedcentral.com/1471-2172/10/6
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kinase phosphorylation occurred only upon stimulation
with OK-432. We have shown that addition of either one
of these inhibitors to OK-432-stimulated MOs did not
change chemokine secretion. On the contrary, with addi-
tion of both of these inhibitors, MCP-1 secretion was
increased, pointing to the existence of other possible sig-
naling pathways. In addition, presence of both inhibi-
tors throughout the isolation and separation of
monocytes blocked the unstimulated secretion of chem-
okines supporting that β integrins are important for
chemokine secretion during the adhesion process. Our
observed Syk phosphorylation upon OK-432 binding
pointed towards an integrin dependence and resonated
with Cuzzola et al [22], who have shown that the MO
interleukin response to Group A Streptococci (GAS) was
dependent on the β2 integrin. We explored whether this
applied to the OK-432-mediated activation of MOs by
adding a blocking anti-CD18 antibody. MCP-1 produc-
tion appears to be partially inhibited by the anti-CD18
antibody. Thus, the β2 integrin may play a role in medi-
ating the effects of OK-432 on MOs. Nevertheless, other
receptors may phosphorylate either Syk or PI-3 kinase or
both and their nature has yet to be established.
OK-432 probably stimulates MOs via TLR2 [15] and/or
TLR4 [25]. In order to study the role of these receptors,
MOs were stimulated in parallel with OK-432, and the
known TLR2 or TLR4 agonists, LTA and LPS, respectively.
Results showed that MOs respond to OK-432 in a similar
fashion to LTA stimulation, thus, arguing for primary
TLR2-dependent stimulation of MOs by OK-432.
A potential candidate for co-stimulation of MOs is
CD36. This receptor has been found to function as a co-
receptor for TLR2 receptor [26]. We determined a
reduced MIP-1β and MCP-1, but an unchanged MIP-1α
response upon employing blocking anti-CD36 antibod-
ies. Thus, CD36 may function as an important receptor
in the OK-432 stimulation of MOs with respect to chem-
okine secretion.
Other co-stimulating receptors than the presently shown
ones may be important for chemokine production following
OK-432 stimulation of MNPs. Examples include CD62L (L-
selectin receptor), a mediator of MOs rolling on and interact-
ing with endothelial cells [27] and CD162 (P-selectin glyco-
protein ligand-1), a promoter in the interaction between
MOs and platelets [28]. Future studies are needed to estab-
lish their roles in OK-432 stimulation in MOs.
The shown MNP stage-dependence for MIP-1α secretion
and adherence-dependent chemokine response to OK-
432 supports the hypothesis that chemokine secretion is
less favoured when MOs are stimulated by OK-432 in pb
compared to extravasal stimulation. This is in line with
our previous observation that TNF-α is primarily secreted
upon OK-432 stimulation after initiation of MO differen-
tiation [17]. The present report thus adds more support to
the notion that OK-432 is a target-seeking substance. Only
when MNPs are stimulated by, e.g., tumor cells or intercel-
lular substances [29], one observes a chemokine response.
The present results argue in favor of chemokine secretion
being an important effector function of MNPs during OK-
432 stimulation. This is important as to designing future
BRM treatments with OK-432. Platinum-based drugs, e.g.,
negatively interfere more with monocyte than lymphocyte
function [31] and should thus be avoided in combination
with OK-432 treatment.
MIP-1α/β and MCP-1 secretion is induced by stimulation
of MOs with OK-432. These chemokines are ligands of the
receptors CXCR1, CCR1, CCR2 and CCR5, present on pol-
ymorphonuclear granulocytes, basophiles, granulocytes,
MOs, Mϕs, DCs, NK cells, T, and B cells [32]. Thus, the
shown chemokine secretion after OK-432 stimulation of
MOs may co-explain the systemic effects of OK-432 on the
immune system. Similar findings were made by Veckman
et al [24] upon stimulating Mϕs with pathogenic live bac-
teria (serotype T1M1 (IH32030)) isolated from a child
with bacteremia. In contrast, we have stimulated mono-
cytes with a heat- and penicillin G-killed, low-virulence
SU strain of S. pyogenes and found very low levels of
RANTES (CCL5). Therefore, it is plausible that virulence
status/degree, strain, and preparation of bacteria influence
chemokine production and MOs may have a different
chemokine profile compared to Mϕs. This becomes espe-
cially interesting when the emphasis is on OK-432 being
a lyophilized, killed S. pyogenes. S. pyogenes is an impor-
tant pathogen causing human disease. The diseases
caused by S. pyogenes range from tonsillitis, impetigo, and
scarlet fever to lethal toxic shock syndrome [13]. The
shown mechanisms of MNP activation by OK-432 thus
shed light on these diseases as well.
Conclusion
We have found that MCP-1 and MIP-1α/β production by
OK-432-stimulated human purified adherent MOs occurs
in most healthy individuals. MIP-1α secretion is mostly
found following differentiation stimuli of MOs to become
Mϕs. Furthermore, MOs stimulated with OK-432 respond
with chemokine secretion dependent on adherent growth
conditions. OK-432 may rely on β2 integrin stimulation.
CD36 modulates the MIP-1β and MCP-1 response to OK-
432. To some extent OK-432 may act as a target-seeking
substance whereby only MOs adhered, e.g., to a target,
secrete substantial amounts of chemokines in part
explaining why OK-432 is suited as a BRM drug.
Methods
Reagents and antibodies
OK-432 (Picibanil) (Chugai Pharmaceutical Co. Ltd.,
Tokyo, Japan) was dissolved in sterile water as a stockBMC Immunology 2009, 10:6 http://www.biomedcentral.com/1471-2172/10/6
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solution with a concentration of 1 KE (Klinische Einheit)/
ml = 0.1 mg/ml. LTA from S. pyogenes and LPS from E.coli
026:B6 (Sigma, St.Louis, MO, USA) were dissolved in PBS
as a stock solution of 5 mg/ml (LTA) and 25 μg/ml (LPS)
and used at a final concentration of 0.5 μg/ml and 1 μg/
ml, respectively. The Syk inhibitor piceatannol (Calbio-
chem, La Jolla, CA, USA) was dissolved in ethanol as a
stock solution with a concentration of 2 mg/ml (8000
μM) and used at a final concentration of 0.5, 1, 30 or 120
μM [18,19,33]. The PI-3 kinase inhibitor, LY294002
(Sigma) was dissolved in sterile water at a concentration
of 5 mg/ml (14.5 mM) and used at a final concentration
of 50 μM. The PI-3 kinase inhibitor, wortmannin (Sigma)
was dissolved in DMSO at a concentration of 1 mg/ml
(2.3 mM) and used at a final concentration of 100 nM.
Azide-free, blocking mouse anti-human CD36 (HyCult,
Uden, The Netherlands) came as a 100 μg/ml stock solu-
tion and anti-mouse rat IgG1 isotype control (R&D Sys-
tems Europe Ltd., Abingdon, Great Britain) was dissolved
in sterile PBS as a 250 μg/ml stock solution. F(ab)
(degraded by pepsin (Sigma)), azide-free, blocking rat
anti-human CD18 (Chemicon International, Temecula,
CA, USA) was dissolved in sterile PBS as a 100 μg/ml stock
solution. Anti-rat IgG2B  isotype control (R&D Systems
Europe Ltd.) was dissolved in sterile PBS as a 500 μg/ml
stock solution.
Patients and controls
Patients admitted to surgery for head and neck squamous
cell carcinoma (HNSCC) gave written consent before par-
ticipating in the study. All patients were males. Patient 1
was 60 years and had tonsillar carcinoma (T3N0M0G1).
Patient 2 had carcinoma of the tongue (T2N2M0G2).
Patient 3 had carcinoma of the basal tongue (T2N2M0G2).
Patient 4 had laryngeal carcinoma (T4N1M0). All patients
donated blood approximately 2 weeks post-operatively as
is appropriate in the event of starting treatment with OK-
432. Whole blood from controls was obtained from ran-
domly selected, healthy donors at Haukeland University
Hospital. As selection was done randomly, age and sex of
donors were not taken into consideration, i.e. not
recorded. The study was approved by the Regional Com-
mittee for Medical Ethics.
Whole blood, PBMC, and monocyte preparation
Whole blood was diluted 1:1 with Ultraculture (Lonza,
Basel, Switzerland), allocated to a 24-well plate (Nunc A/
S, Roskilde, Denmark) and upon experiment comple-
tion, the supernatant was collected after the whole
blood/Ultraculture mixture was centrifuged. PBMCs
were separated by density gradient centrifugation with
Lymphoprep® (Nycomed, Oslo, Norway) as density gra-
dient medium in LeukoSep tubes (Greiner-Bio One
GmbH, Frickenhausen, Germany). MOs were, unless
otherwise stated, isolated from blood by gradient centrif-
ugation followed by adherence to plastic. The PBMC
yield of 7 ml blood (6 × 105 cells/well) was allocated to
a 24-well plate (Nunc) with RPMI 1640 (Lonza) supple-
mented with amphotericin B (2.5 μg/ml) and glucose
(2% v/v) (both Sigma), HEPES (1% v/v), L-glutamine
(1% v/v), penicillin (100 IU/ml), streptomycin (100 μg/
ml), sodium bicarbonate (2.7% v/v), sodium pyruvate
(1% v/v)(all from Lonza) and 20% AB serum to a total
volume of 0.5 ml/well. After 40 minutes pre-incubation,
the adherent MOs were purified by washing, and then
cultured in complete RPMI 1640 (Lonza)/20% AB serum
with 0.5 ml/well. The method yields in general cultures
which contain at least 75% MOs, as determined by non-
specific esterase stain (NSES), and more than 90% viable
cells, as tested by tryphan blue stain. In some experi-
ments, MOs were also isolated using the negative isola-
tion kit (Dynal Biotech, Oslo, Norway) according to the
manufacturer's protocol. Briefly, PBMCs, isolated by gra-
dient centrifugation using Lymphoprep-containing Leu-
koSep tubes, were resuspended in PBS/0.1% bovine
serum albumin (BSA) (Sigma) and exposed to an equal
mixture of blocking reagent and antibody mix for 10 min
at 4°C. After 10 min, PBMCs were washed, added fresh
PBS/0.1% BSA, added to washed beads, and incubated
for 15 min with gentle tilting and rotation at 4°C. After
incubation, resuspended rosettes were pipetted and
placed in the Dynal MPC magnet for 5 min. The super-
natant was collected and placed in the Dynal MPC mag-
net for an additional 2 min. The collected MO-pure
supernatant (95% purity – NSES) was washed, cells
counted, and added to a 24-well plate.
Experimental conditions
In different experimental series, MOs (1 × 105 cells/well)
were cultured either with piceatannol (0.5, 1, 30 or 120
μM – final concentration), LY294002 (50 μM – final con-
centration), wortmannin (100 nM – final concentration)
or anti-CD36 (2.5 μg/ml – final concentration) or anti-
mouse IgG1 isotype control (2.5 μg/ml – final concentra-
tion) or pepsin-degraded (Fab) anti-CD18 (12.5 μg/ml –
final concentration) or anti-rat IgG2B isotype control (12.5
μg/ml – final concentration) for 30 min before OK-432
(0.01 KE/ml – final concentration) was added and after 24
hours the supernatants were collected and stored at -80°C
for further analysis.
Total RNA extraction
In some experiments, total RNA was isolated immediately
after harvesting MOs (24 hours post-stimulation), using
the RNeasy Minikit's (Qiagen, Hilden, Germany) protocol
for isolation of total RNA from animal cells grown in
monolayer, as recommended by the manufacturer.
Briefly, adherent MOs were added 350 μl lysis bufferBMC Immunology 2009, 10:6 http://www.biomedcentral.com/1471-2172/10/6
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(buffer RLT containing beta-mercaptoethanol (Sigma)),
homogenized by vortexing for 30 s, and the homogenate
was applied to an Rneasy spin column after addition of
ethanol in order to bind total RNA to the membrane.
Contaminants were removed by washing with buffers
RW1 and RPE, and total RNA was eluted using water. In
addition, total RNA was isolated from MOs of normal
blood donors and subsequently pooled for use in generat-
ing the standard curve.
Reverse transcription
TaqMan RT reagents (Applied Biosystems, Foster City, CA,
USA) were used to reverse transcribe total RNA from OK-
432-stimulated MOs obtained from normal blood
donors. Final concentration of the RT reaction was 1 ×
TaqMan RT buffer, 5.5 mM MgCl 2, 2 mM dNTP mixture
(500 μM of each dNTP), 2.5 μM random hexamers, 0.4
units/μl RNase inhibitor, 2.5 units/μl Multiscribe RT, 5–
25 ng RNA, and DEPC water to a total volume of 50 μl.
The RT thermal cycling was performed on a Mastercycler
gradient thermal cycler (Eppendorf, Hamburg, Germany)
under the following conditions: primer incubation for 10
min at 25°C, reverse transcription for 30 minutes at 48°C,
and inactivation of reverse transcriptase for 5 minutes at
95°C.
Primer and probe design
Primer and probes for the TaqMan assays were designed
using the Primer Express software (Applied Biosystems).
Intron-spanning primers were used to prevent amplifica-
tion of genomic DNA. The candidate genes were MCP-1
[GenBank: NM_002982] (70 bp-amplicon); primers: (F)
5'-CTCTCGCCTCCAGCATGAA-3', (R) 5'-GGAATGAAG-
GTGGCTGCTATGA-3', probe: 5'-CCGCCCTTCTGT-
GCCTGCTGC-3'and the housekeeping gene used was
CD68 [GeneBank: BC015557] (67 bp-amplicon); prim-
ers: (F) 5'-CCCCACGCAGCAAAGTG-3', (R) 5'-CCAG-
GGGTGCTTGGAGATCT-3, probe: 5'-TCTCGGCTCAGAA
TGCATCCCTTCG-3'). Designed primers and probes were
purchased from MedProbe (Oslo, Norway).
Real-time quantitative RT-PCR analysis
The ABI PRISM 7700 Sequence Detection System
(Applied Biosystems) with 96-well plates was used to per-
form real-time quantitative RT-PCR. Reactions were car-
ried out in a total volume of 25 μl containing 12.5 μl of 2
× TaqMan Universal PCR Master Mix (Applied Biosys-
tems), 300 nM (0.25 μl) forward primer, 300 nM (0.25
μl) reverse primer, 200 nM (1 μl) TaqMan probe, 8 μl
water, and 3 μl cDNA template. Thermocycler conditions
were as follows: incubation for 2 minutes at 50°C, fol-
lowed by incubation for 10 minutes at 95°C and 40 cycles
of two-step (denaturing for 15 seconds at 95°C followed
by annealing/extension for 1 minute at 60°C) PCR. As a
reference gene, CD68 was used to normalize the gene
expression of MCP-1. To generate a standard curve for rel-
ative gene expression determination, cDNA synthesized
from pooled total RNA of MOs obtained from healthy
blood donors was used. The standard curves generated for
the cDNA analyzed had slopes with a mean of -3.3.
Western blot analysis
MOs from 7 ml blood were isolated by gradient centrifu-
gation in Lymphoprep-containing LeukoSep tubes, fol-
lowed by the monocyte negative isolation kit (Dynal
Biotech), allowed to adhere for 40 minutes, after which
piceatannol or LY294002 or diluent control was added for
30 min, followed by incubation with OK-432 for 15 min.
Upon experiment completion, cells were washed once
with cold PBS, added lysis buffer (50 mM Tris-HCl, pH
7.4, 1% NP40, 0.25% sodium deoxycholate, 150 mM
NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM sodium
orthovanadate, 1 mM NaF, and 1× complete proteinase
inhibitor (Roche, Nutley, NJ, USA)) and scraped gently
using a cell scraper. The cell lysate was clarified by centrif-
ugation at 16,000 g for one minute at 4°C. Protein levels
were measured using the Bio-Rad BCA Protein Assay (Bio-
Rad, Hercules, CA, USA). Samples were added 1× loading
buffer and the lysate was boiled for 5 minutes. Samples (6
μg/lane) and a Precision Plus Protein Kaleidoscope stand-
ard (Bio-Rad) were electrophoresed on a 10% SDS poly-
acrylamide gel for 60 minutes at 200 V and transferred to
nitrocellulose membranes (Bio-Rad) in electroblotting
buffer (25 mM Tris base, 0.2 M glycine, and 20% metha-
nol) for 60 minutes at 100 V. Membrane was blocked with
5% BSA in TBS-Tween for one hour at RT with gentle tilt-
ing. The blots were exposed either to a polyclonal anti-
body against phosphorylated Syk or PI3 kinase p85/p55
or total Syk or total PI3 kinase p85 (all: Cell Signaling,
Beverly, MA, USA) (all: 1:1000 in 5% BSA in TBS-Tween)
overnight at 4°C with gentle shaking. After washing, an
HRP-linked goat anti-rabbit IgG (H + L) antibody (Bio-
Rad) (1:2000) was added for one hour at room tempera-
ture with gentle tilting. Proteins were detected using lumi-
nol/enhancer/hydrogen peroxide – based ECL and
visualized on the Molecular Imager ChemiDoc XRS Sys-
tem (Bio-Rad).
Multiplex cytokine analysis
Chemokines in supernatants were detected using the
Luminex immunobead technology. A 25-plex or 5-plex
chemokine kit (all from Invitrogen/Biosource, Carlsbad,
CA, USA), were used to analyze cytokine levels in super-
natants from successfully completed experiments. In
short, antibody-coupled beads were incubated with target
analyte after which they were incubated with biotinylated
detection antibody before finally being incubated with
streptavidin-phycoerythrin. Standard sensitivity was 10
pg/ml (MIP-1α, MIP-1β). Samples were then read by the
Bio-Plex array reader (Invitrogen/Biosource), usingBMC Immunology 2009, 10:6 http://www.biomedcentral.com/1471-2172/10/6
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Luminex fluorescent bead-based technology (Luminex
Corporation Austin, TX, USA).
MCP-1 protein analysis
The contents of MCP-1 in supernatants were determined
by enzyme-linked immunosorbant assay kit (ELISA) man-
ufactured by R&D Systems (R&D Systems). All procedures
were performed according to the specifications of the
manufacturer. In short, 96-well microtiter plates (Costar
Corning, NY, USA) were coated overnight at room tem-
perature with monoclonal mouse anti-human MCP-1
capture antibodies. Diluted samples and recombinant
human MCP-1 standard were added and incubated for 2
h at room temperature followed by addition of bioti-
nylated polyclonal goat anti-human MCP-1. The plates
were incubated for 20 minutes at room temperature with
streptavidin-conjugated horseradish peroxidase. Tetra-
methyl-benzidine (TMB) (Sigma) and H2O2 were used as
substrate. Absorbency values were measured at 450 nm
using Softmax Pro version 4.0 on an Emax Precision
microtiter plate reader (Molecular Devices, Sunnyvale,
CA, USA). The lower detection level was 15.62 pg/ml.
Chemokine levels obtained with media controls (after 24
h) were substracted from those obtained with OK-432-,
LTA-, LPS-stimulation. All media controls tested directly
after monocyte purification had nondetectable chemok-
ine levels.
Statistical analyses
The statistical program package Statistical Package for the
Social Sciences (Ver. 16 SPSS, Chicago, Ill., USA) was
used. Chemokine levels and expression were compared by
the Wilcoxon signed-rank test (two-tailed). Differences
were considered significant at p < 0.05.
Abbreviations
BRM: biological response modifier; HNSCC: head and
neck squamous cell carcinoma; MIP: macrophage inflam-
matory protein; MCP: monocyte chemoattractant protein;
pb: peripheral blood; PI: phosphoinositide; pSyk: phos-
phoSyk; TLR: Toll-like receptor.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CO performed the Western blot analysis, Multiplex analy-
sis, all the experiments and data analysis. HS did the RT-
PCR experiments and analysis. KB operated the Luminex
machine. JO provided OK-432. CO and HJA were respon-
sible for the concept and design of the experiments and
primarily writing the manuscript. All authors have read
and approved the manuscript.
Acknowledgements
This work has been supported by the Norwegian Cancer Society and the 
Strategic Research Program at Helse Bergen, Norway. We thank Dagny 
Ann Sandnes for expert ELISA analysis, Petra Vogelsang for assistance with 
the Western blot/Molecular Imager ChemiDoc XRS System, Broegelmann 
Research Laboratory for providing lab and instruments for Western blot 
analysis and The Research Core Facility (FFS) at Haukeland University Hos-
pital for general lab and instrument access.
References
1. Sakamoto J, Teramukai S, Watanabe Y, Hayata Y, Okayasu T, Naka-
zato H, Ohashi Y: Meta-analysis of Adjuvant Immunochemo-
therapy Using OK-432 in Patients With Resected Non-
Small-Cell Lung Cancer.  J Immunother 2001, 24:250-256.
2. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J:
Efficacy of adjuvant immunochemotherapy with polysaccha-
ride K for patients with curative resections of gastric cancer.
Cancer Immunol Immunother 2006, 56(6):905-911.
3. Ogita S, Tsuto T, Deguchi E, Tokiwa K, Nagashima M, Iwai N: OK-
432 therapy for unresectable lymphangiomas in children.  J
Pediatr Surg 1991, 26:263-8.
4. Okamoto M, Ohe G, Oshikawa T, Nishikawa H, Furuichi S, Yoshida
H, Matsuno T, Saito M, Sato M: Induction of Th1-type cytokines
by lipoteichoic acid-related preparation isolated from OK-
432, a penicillin-killed streptococcal agent.  Immunopharmacol-
ogy 2000, 49:363-76.
5. Baran J, Baj-Krzyworzeka M, Weglarczyk K, Ruggiero I, Zembala M:
Modulation of monocyte-tumour cell interactions by Myco-
bacterium vaccae.  Cancer Immunol Immunother 2004, 53:1127-34.
6. Ooi VE, Liu F: Immunomodulation and anti-cancer activity of
polysaccharide-protein complexes.  Curr Med Chem 2000,
7:715-29.
7. Moschos SJ, Edington HD, Lan SR, Rao UN, Jukic D, Shipe-Spotloe J,
Kirkwood JM: Neoadjuvant treatment of regional stage IIIB
melanoma with high-dose interferon alfa-2b induces objec-
tive tumor regression in association with modulation of
tumor infiltrating host cellular immune responses.  J Clin Oncol
2006, 24:3164-71.
8. Knecht R, Peters S, Solbach C, Baghi M, Gstottner W, Hambek M:
EGFR antibody-supplemented TPE-chemotherapy. Preclini-
cal investigations to a novel approach for head and neck can-
cer induction treatment.  Anticancer Res 2003, 23:4789-95.
9. Kumazawa H, Yamashita T, Tachikawa T, Minamino M, Nakata Y:
Local injection of OK-432/fibrinogen gel into head and neck
carcinomas.  Eur J Cancer 1994, 30A:1741-4.
10. Naito K, Ueda Y, Itoh T, Fuji N, Shimizu K, Yano Y, Yamamoto Y,
Imura K, Kohara J, Iwamoto A, et al.: Mature dendritic cells gen-
erated from patient-derived peripheral blood monocytes in
one-step culture using streptococcal preparation OK-432
exert an enhanced antigen-presenting capacity.  Int J Oncol
2006, 28:1481-9.
11. Knipping S, Goetze G, Neumann K, Bloching M: Sclerotherapy of
cervical cysts with Picibanil (OK-432).  Eur Arch Otorhinolaryngol
2006, 264:423-7.
12. Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M: Biolog-
ical effect of OK-432 (picibanil) and possible application to
dendritic cell therapy.  Anticancer Res 2004, 24:3295-301.
13. Cleary PP: Streptococcus moves inward.  Nat Med 2006,
12:384-6.
14. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meer-
schaut S, Beschin A, Raes G, De Baetselier P: Classical and alterna-
tive activation of mononuclear phagocytes: picking the best
of both worlds for tumor promotion.  Immunobiology 2006,
211:487-501.
15. Graveline R, Segura M, Radzioch D, Gottschalk M: TLR2-depend-
ent recognition of Streptococcus suis is modulated by the
presence of capsular polysaccharide which modifies macro-
phage responsiveness.  Int Immunol 2007, 19:375-89.
16. Moser B, Wolf M, Walz A, Loetscher P: Chemokines: multiple
levels of leukocyte migration control.  Trends Immunol 2004,
25:75-8.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Immunology 2009, 10:6 http://www.biomedcentral.com/1471-2172/10/6
Page 11 of 11
(page number not for citation purposes)
17. Olsnes C, Stavang H, Olofsson J, Aarstad HJ: TNF-alpha is
secreted by monocytes in transit to become macrophages,
but not by peripheral blood monocytes, following OK-432
(lyophilized S. pyogenes) stimulation.  Scand J Immunol 2007,
66:684-93.
18. Schenkel AR, Mamdouh Z, Muller WA: Locomotion of monocytes
on endothelium is a critical step during extravasation.  Nat
Immunol 2004, 5:393-400.
19. Vines CM, Potter JW, Xu Y, Geahlen RL, Costello PS, Tybulewicz VL,
Lowell CA, Chang PW, Gresham HD, Willman CL: Inhibition of
beta 2 integrin receptor and Syk kinase signaling in mono-
cytes by the Src family kinase Fgr.  Immunity 2001, 15:507-19.
20. Reyes-Reyes M, Mora N, Gonzalez G, Rosales C: beta1 and beta2
integrins activate different signalling pathways in mono-
cytes.  Biochem J 2002, 363:273-80.
21. Butler B, Williams MP, Blystone SD: Ligand-dependent activation
of integrin alpha vbeta 3.  J Biol Chem 2003, 278:5264-70.
22. Cuzzola M, Mancuso G, Beninati C, Biondo C, Genovese F, Tomasello
F, Flo TH, Espevik T, Teti G: Beta 2 integrins are involved in
cytokine responses to whole Gram-positive bacteria.  J Immu-
nol 2000, 164:5871-6.
23. Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor
JL: CD36 and macrophages in atherosclerosis.  Cardiovasc Res
2007, 75:468-77.
24. Veckman V, Miettinen M, Matikainen S, Lande R, Giacomini E, Coccia
EM, Julkunen I: Lactobacilli and streptococci induce inflamma-
tory chemokine production in human macrophages that
stimulates Th1 cell chemotaxis.  J Leukoc Biol 2003, 74:395-402.
25. Okamoto M, Oshikawa T, Tano T, Ahmed SU, Kan S, Sasai A, Akashi
S, Miyake K, Moriya Y, Ryoma Y, et al.: Mechanism of anticancer
host response induced by OK-432, a streptococcal prepara-
tion, mediated by phagocytosis and Toll-like receptor 4 sign-
aling.  J Immunother 2006, 29:78-86.
26. Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Har-
tung T, Triantafilou K: Membrane sorting of toll-like receptor
(TLR)-2/6 and TLR2/1 heterodimers at the cell surface
determines heterotypic associations with CD36 and intracel-
lular targeting.  J Biol Chem 2006, 281:31002-11.
27. Tacke F, Randolph GJ: Migratory fate and differentiation of
blood monocyte subsets.  Immunobiology 2006, 211:609-18.
28. Ma YQ, Plow EF, Geng JG: P-selectin binding to P-selectin glyc-
oprotein ligand-1 induces an intermediate state of
alphaMbeta2 activation and acts cooperatively with extra-
cellular stimuli to support maximal adhesion of human neu-
trophils.  Blood 2004, 104:2549-56.
29. Coussens LM, Werb Z: Inflammation and cancer.  Nature 2002,
420:860-7.
30. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos
C, Mertelsmann R, Engelhardt R: Phase II trial of intravenous
endotoxin in patients with colorectal and non-small cell lung
cancer.  Eur J Cancer 1996, 32A:1712-8.
31. Briegert M, Kaina B: Human monocytes, but not dendritic cells
derived from them, are defective in base excision repair and
hypersensitive to methylating agents.  Cancer Res 2007,
67:26-31.
32. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The
chemokine system in diverse forms of macrophage activa-
tion and polarization.  Trends Immunol 2004, 25:677-8.
33. Huang ZY, Barreda DR, Worth RG, Indik ZK, Kim MK, Chien P, Sch-
reiber AD: Differential kinase requirements in human and
mouse Fc-gamma receptor phagocytosis and endocytosis.  J
Leukoc Biol 2006, 80:1553-62.